Navigation Links
ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
Date:9/11/2009

th year running and the awards ceremony will take place on November 18, 2009 in London.

Patrik De Haes, CEO of ThromboGenics, commented, "We are very pleased to have been shortlisted for both the Biotech Company of the Year and Licensing Deal of the Year awards at this prestigious awards event. The nominations are a testament to the significant achievements and progress ThromboGenics has made over the last year. The Company is now in the best position to achieve its aim of becoming a profitable, integrated Company focused on cutting edge ophthalmic medicines. We are very proud to be nominated amongst some of the most successful companies in the industry, and look forward to the results in November."

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

About Scrip World Pharmaceutical
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... RESTON, Va. (PRWEB) October 24, 2014 ... (WEDI), the nation’s leading nonprofit authority on ... in healthcare information exchange, announces its appointment of ... Privacy Workgroup. The workgroup leaders include:, ... Optum ,     Erik Pupo, Specialist Leader, Deloitte ...
(Date:10/25/2014)... Addison, TX (PRWEB) October 24, 2014 ... skincare products, announced the winners of its “Reflect Your ... who have not only seen a difference in their ... also experienced a new outlook on life as a ... Youth” contest originated as an effort by Nerium International ...
(Date:10/25/2014)... 2014 A new way to produce ... of current skin grafting technologies, it also speeds up ... method, outlined in the October issue of STEM CELLS ... skin injuries that result from severe burns and chronic ... skin’s regenerative elements. These wounds heal by contraction, with ...
(Date:10/25/2014)... , October 24, 2014 ... clinical-stage pharmaceutical company focused on the development of oral ... Nadav Kidron will present at FireRock Capital,s ... Capital,s Annual Micro-Cap Conference ,Date: Tuesday, October 28, 2014 ... New York City , ...
Breaking Biology Technology:WEDI Appoints Four New Security and Privacy Workgroup Co-chairs 2Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3
... an Educational Webinar "How Organizations Can Make the Transition ... featuring Virtify, Inc. , , CAMBRIDGE, Mass., ... ), the market leader in Enterprise Content Compliance solutions ... ), a provider of Enterprise Compliance and Quality ...
... -- China-Biotics,Inc. (Nasdaq: CHBT ) ("China-Biotics," ... manufacture, research, development, marketing and,distribution of probiotics products ... management will present at the upcoming,China Rising Conference ... on May 18,2009. , ...
... April 30 Amicus Therapeutics (Nasdaq: FOLD ... the regular close of markets on Thursday, May 7, ... live conference call and webcast that afternoon at 5 ... conference call at 5 p.m. EDT by dialing 877-874-1565 ...
Cached Biology Technology:Event Alert: 'SPL R4 Compliance and its Impact on Regulatory Submission Processes' 2Event Alert: 'SPL R4 Compliance and its Impact on Regulatory Submission Processes' 3China-Biotics, Inc. to Present at CCG Investor Relations' China Rising Conference 2China-Biotics, Inc. to Present at CCG Investor Relations' China Rising Conference 3Amicus Therapeutics Announces First Quarter 2009 Financial Results Release Date 2
(Date:10/22/2014)... Oct. 20, 2014 The Nano-Bio Manufacturing Consortium ... Force Research Laboratory (AFRL), has chosen a project proposed ... the University of Arizona College of Medicine – ... AzCIM project,s goal is to assess different sweat collection ... volumes of sweat under a variety of human-body conditions, ...
(Date:10/18/2014)... stress-related psychiatric disorders are associated with increased ... mechanisms underlying this relation are unknown. Understanding ... of targeted preventive strategies and new or ... work is presented at the European College ... international group of researchers from Germany and ...
(Date:10/17/2014)... available in German . ... every day in order to reproduce? And why are there ... of the latest issue of the research journal Molecular ... biologist Steven Ramm from Bielefeld University Bielefeld has compiled this ... unusual for a female to copulate with several males in ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Researchers find why depression and aging linked to increased disease risk 2Sperm wars 2
... of time, knowledge and training in health promotion and ... the top barriers to including effective physical activity counseling ... The University of Texas School of Public Health, part ... Houston (UTHealth). "Individual and organization barriers must be ...
... DNA can trigger tumorigenesis. Researchers from Ludwig-Maximilians-Universitaet (LMU) ... a protein involved in the repair and signaling ... light on the origins of neurodegenerative diseases and ... or environmental toxins can cause double-stranded breaks in ...
... have found that acceptance of the site of a ... economic background. Writing in the International Journal of Environmental ... more often have a positive opinion on the location ... While the actual quantities of nuclear waste around the ...
Cached Biology News:UTHealth study addresses barriers to physical activity counseling 2UTHealth study addresses barriers to physical activity counseling 3Where to put nuclear waste? 2
... Synthetic peptide derived from the internal ... Specificity: Specific for the junctophilin-1 protein. ... brain and skeletal muscle homogenates frozen ... Applications: Western blotting Immunohistochemistry(froz) ImmunofluorescenceStorage: ...
Laminin beta-1/gamma-1 (612C10)...
100 ug affinity purified rabbit anti-JIP-1 polyclonal antibody. Reacts with mouse and rat. Perform well in Western blotting. Other applications have not been tested. Storage Temperature: -20C Shi...
XBP-1 (F-4)...
Biology Products: